Nvidia has introduced the BioNeMo Agent Toolkit, a software suite designed to enhance AI capabilities in biology, chemistry, genomics, and drug discovery. The toolkit integrates Nvidia's life sciences libraries, models, and computing tech to enable AI agents to perform scientific tasks, analyze data, and recommend actions. Over 50 organizations, including Lilly, Natera, and OpenAI, are already using it to accelerate research workflows. This innovation aims to reduce the time needed for computational experiments and improve scientific discovery efficiency.
Bitget has introduced Stock+, a new feature allowing users to buy real US stocks directly using USDC and other digital assets. This innovation bridges crypto and traditional finance by enabling stock ownership through a single platform without interm...
Micron Technology's stock fell about 12% due to a broad tech sell-off, wiping billions off its market value. However, Deutsche Bank reports a looming multi-year memory shortage driven by rapid AI demand, particularly for high bandwidth memory (HBM) a...
Global markets saw a sharp selloff led by major chipmakers like Nvidia, Intel, and Samsung amid investor anxiety ahead of Micron's earnings report, a key indicator for AI demand. The Nasdaq dropped 2.8%, and South Korea's Kospi plunged 10% as memory ...
NVIDIA reported Q1 FY2027 revenue of $81.61 billion, up 85.2% year-over-year, driven by a 92% surge in its Data Center segment. Despite China export restrictions excluding some revenue, the company projects $91 billion revenue for Q2 with strong marg...
Alphabet is expected to receive a timely upgrade due to its renewed AI-driven growth momentum and strategic moves like an $85 billion secondary offering and Berkshire Hathaway's $10 billion stake. These developments highlight Alphabet's key role in t...
